Roles of angiotensin Ⅱ receptors in tumor

doi:10.3760/cma.j.issn.1673-422X.2014.05.001

Abstract

Abstract: Angiotensin (AngⅡ), a main effector peptide of the reninangiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Recent studies have implicated that it correlates with tumor growth, angiogenesis, metastasis and it has drawn more and more attention. Many studies show that Ang ⅡAT1R/AT2R play crucial roles in tumor growth, metastasis, invasion and tumor angiogenesis, which are formed new targets for treating malignant tumors.

Key words: Angiotensin Ⅱ, Neoplasms, Receptor, angiotensin, type 1, Receptor, angiotensin, type 2, Angiotensin Ⅱ type 1 receptor blockers

Ding Xiangli, Wang Haifeng, Yang Delin, et al. Roles of angiotensin Ⅱ receptors in tumor[J]. Journal of International Oncology, 2014, 41(5): 321-323.

References

［1］ Doi C, Egashira N, Kawabata A, et al. Angiotensin Ⅱ type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice［J］. BMC cancer， 2010， 10(1):67. ［2］ PtasinskaWnuk D, Lawnicka H, Mucha S, et al. Angiotensins inhibit cell growth in GH3 lactosomatotroph pituitary tumor cell culture: a possible involvement of the p44/42 and p38 MAPK pathways［J］. Scient World J, 2012, 2012:189290. ［3］ Arafat HA, Gong Q, Chipitsyna G, et al. Antihypertensives as novel antineoplastics: angiotensinIconverting enzyme inhibitors and angiotensin Ⅱ type 1 receptor blockers in pancreatic ductal adenocarcinoma［J］. J Am Coll Surg, 2007, 204(5):996-1005. ［4］ Arrieta O, PinedaOlvera B, GuevaraSalazar P, et al. Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis［J］. Br J Cancer, 2008, 99(1):160-166. ［5］ Shirotake S, Miyajima A, Kosaka T, et al. Angiotensin Ⅱ type 1 receptor expression and microvessel density in human bladder cancer［J］. Urology, 2011, 77(4):1009. ［6］ DolleyHitze T, Jouan F, Martin B, et al. Angiotensin2 receptors (AT1R and AT2R), new prognostic factors for renal clearcell carcinoma?［J］. Br J Cancer, 2010, 103(11):1698-1705. ［7］ Shirotake S, Miyajima A, Kosaka T, et al. Regulation of monocyte chemoattractant protein1 through angiotensin Ⅱ type 1 receptor in prostate cancer［J］. Am J Pathol, 2012, 180(3):1008-1016. ［8］ Rcken C, Rhl FW, Diebler E, et al. The angiotensin Ⅱ/angiotensin Ⅱ receptor system correlates with nodal spread in intestinal type gastric cancer［J］. Cancer Epidemiol Biomarkers Prev, 2007, 16(6):1206-1212. ［9］ CarlMcGrath S, Ebert MP, Lendeckel U, et al. Expression of the local angiotensin Ⅱ system in gastric cancer may facilitate lymphatic invasion and nodal spread［J］. Cancer Biol Ther, 2007, 6(8):1218-1226. ［10］ Munn LL. Dynamics of tissue topology during cancer invasion and metastasis［J］. Phys Biol, 2013, 10(6):65003. ［11］ Ino K, Shibata K, Yamamoto E, et al. Role of the reninangiotensin system in gynecologic cancers［J］. Curr Cancer Drug Tar, 2011, 11(4):405-411. ［12］ Buharalioglu CK, Song CY, Yaghini FA, et al. Angiotensin Ⅱ induced process of angiogenesis is mediated by spleen tyrosine kinase via VEGF receptor1 phosphorylation［J］. Am J Physiol Heart Circ Physiol, 2011, 301(3):H1043-1055. ［13］ Imai N, Hashimoto T, Kihara M, et al. Roles for host and tumor angiotensin Ⅱ type 1 receptor in tumor growth and tumorassociated angiogenesis［J］. Lab Invest, 2007, 87(2):189-198. ［14］ Lau ST, Leung PS. Role of the RAS in pancreatic cancer［J］. Curr Cancer Drug Targets, 2011, 11(4):412-420. ［15］王亮, 何裕隆, 张常华, 等. 血管紧张素转换酶抑制剂和血管紧张素Ⅱ受体拮抗剂抑制胃癌淋巴管生成的实验研究［J］. 消化肿瘤杂志（电子版）, 2008, 1(1)34-39. ［16］ Pickel L, Matsuzuka T, Doi C, et al. Overexpression of angiotensinⅡ type 2 receptor gene induces cell death in lung adenocarcinoma cells［J］. Cancer Biol Ther, 2010, 9(4)：277-285. ［17］ Louis SN, Chow L, Rezmann L, et al. Expression and function of ATIP/MTUS1 in human prostate cancer cell lines［J］. Prostate, 2010, 70(14):1563-1574. ［18］ Clere N, Corre I, Faure S, et al. Deficiency or blockade of angiotensin Ⅱ type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis［J］. Int J Cancer, 2010, 127(10):2279-2291.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.